CTOs on the Move

Amicus Therapeutics

www.amicusrx.com

 
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.amicusrx.com
  • 1 Cedar Brook Drive
    Cranbury, NJ USA 08512
  • Phone: 609.662.2000

Executives

Name Title Contact Details

Similar Companies

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.

Highfive Vet Wholesale

Automated purchasing for vet clinics | Less mundane tasks. More time for your mission.

Septodent

Septodent is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PHC Holdings

This is the website of PHC Holdings Corporation, which is a global innovator in healthcare solutions.

Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.